Skip to main content
Signal8
Launch Terminal

LB PHARMACEUTICALS INC (LBRX)

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

LB Pharmaceuticals Inc Common Stock logo

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRXHealthcare
-1.12%$39.70
AH$41.19+3.75%vs close
Mkt Cap$1.28B
Float24.22M
O/S32.26M
Vol
$ Vol
RVOL
Inst Own92.5%
SI23.0%
Earnings
Dilution
LB Pharmaceuticals Inc Common Stock logoNASDAQ:LBRX$39.70-1.12%
Phase Distribution
6 lead-sponsored trials·3 active·3 completed
Phase 12
Phase 22
Phase 32
Status Overview
Recruiting3
Completed3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Recruiting

    Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    LB-102 (50 mg tablet), LB-102 (100 mg tablet)

    Schizophrenia

    Enrollment
    456
    Start
    Mar 2026
    Primary Completion
    Jun 2027est.
    Completion
    Oct 2027est.
    NCT07363577
  • Phase 3
    Recruiting

    52-week Open Label Safety-Tolerability Study

    LB-102

    Schizophrenia

    Enrollment
    900
    Start
    Apr 2026
    Primary Completion
    Dec 2028est.
    Completion
    Apr 2029est.
    NCT07369154
  • Phase 2
    Completed

    Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

    LB-102

    Schizophrenia

    Enrollment
    359
    Start
    Nov 2023
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT06179108
  • Phase 2
    Recruiting

    Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

    LB-102

    Bipolar I Disorder

    Enrollment
    320
    Start
    Jan 2026
    Primary Completion
    Feb 2028est.
    Completion
    Feb 2028est.
    NCT07494305
  • Phase 1
    Completed

    Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

    LB-102

    Schizophrenia

    Enrollment
    64
    Start
    Jan 2020
    Primary Completion
    Jul 2020
    Completion
    Nov 2020
    NCT04187560
  • Phase 1
    Completed

    Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

    LB-102

    Schizophrenia

    Enrollment
    16
    Start
    Jan 2021
    Primary Completion
    Sep 2021
    Completion
    Nov 2021
    NCT04588129
Search ClinicalTrials.gov for “Lb Pharmaceuticals”